Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|January 20, 2025

Treatment Choices For PPD and Peripartum Depression

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss the strategic decision-making process for choosing among selective serotonin reuptake inhibitors (SSRIs), rapid-onset treatments like zuranolone, and nonmedication therapies for postpartum depression (PPD), emphasizing the importance of treatment speed, severity of symptoms, and patient preferences.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

5 experts are featured in this series

Differentiating Agitation from Depression, Anxiety, and Psychosis

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

5 experts are featured in this series

Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

Screening for MDD: Distinguishing Depression From Grief and Medical Mimics

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Recognizing MDD in Practice: Presentation, Risk Factors, and Delayed Diagnosis

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness